Toufik Haddad, MD
Interventional Cardiology · Omaha, NENPI 1932541000
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,819 of the $14,249 with a category attached, or 61.9%. 22 manufacturers reported payments, led by Boston Scientific at 33.0% of the total. Reporting peaked in 2019 at $4,129 and has fallen 64.4% since, to $1,469 in 2025.
Across 218 payments — averaging $65.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Abbott$4K
- Terumo Medical Corporation$1K
- Shockwave Medical, Inc$1K
- Medtronic$1K
- Edwards Lifesciences$636
- plus $1K from 16 others
What the payments were for
- Travel & lodging$5,43038%
- Food & beverage$8,81962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 68 | $4,698 |
| Abbott | 30 | $3,588 |
| Terumo Medical Corporation | 15 | $1,491 |
| Shockwave Medical, Inc | 30 | $1,460 |
| Medtronic(2 entities) | 20 | $1,072 |
| Edwards Lifesciences | 10 | $636 |
| Abiomed | 9 | $390 |
| Inari Medical, Inc. | 1 | $197 |
| Cardiovascular Systems Inc. | 7 | $162 |
| Johnson & Johnson | 3 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $108 |
| Cardiva Medical, Inc. | 1 | $60 |
| Pfizer | 4 | $53 |
| Novartis | 2 | $35 |
| Endotronix, Inc. | 1 | $23 |
| W. L. Gore & Associates, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| GE HealthCare | 1 | $17 |
| Biosense Webster, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Amgen | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CROSSBOSS$2,268
- Omnilink Elite vascular stent system$1,212
- TR Band$1,125
- PERCLOSE PROGLIDE$992
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$550
- Impella$240
- LINQ II$240
- FLOWTRIEVER CATHETER, S$197
- CT THROMBECTOMY SYSTEM KIT$197
- XIENCE SKYPOINT$192
- ONYX FRONTIER$159
- GENERAL - THERAPIES$146
- CARDIOMEMS$144
- Mitra Clip system$134
- Resolute$133
- COMPLETE SE VASCULAR$131
- GENERAL VASCULAR ACCESS$130
- MitraClip System$128
- XARELTO$125
- Watchman$122
How this compares
$14,249 in reported general payments places this provider in the 70th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $109,244 |
| EntrestoSacubitril/Valsartan | 86 | $73,169 |
| XareltoRivaroxaban | 57 | $40,704 |
| Repatha SureclickEvolocumab | 33 | $26,911 |
| FarxigaDapagliflozin Propanediol | 35 | $21,468 |
| Metoprolol Succinate | 287 | $3,652 |
| Ranolazine ErRanolazine | 39 | $3,129 |
| Midodrine Hcl | 23 | $2,401 |
| Atorvastatin Calcium | 199 | $1,884 |
| Potassium Chloride | 109 | $1,520 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 35 | $895 |
| Losartan Potassium | 90 | $683 |
| Rosuvastatin Calcium | 77 | $681 |
| Amlodipine Besylate | 120 | $609 |
| Torsemide | 24 | $488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $109,244109 claims |
| NovartisEntresto | $35 | $73,16986 claims |
| Johnson & JohnsonXarelto | $159 | $40,70457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.